Agoracom: Small Cap Investment - Zenith Epigenetics - Dec 2016 article - apologies if already posted. Didn't see it in "Link Library"

...We Welcome You to the Zenith Epigenetics Hub withIn The AGORACOM COMMUNITY!

Zenith's BET Inhibitor ZEN-3694 is Currently Being Evaluated in Multiple Oncology Clinical Trials

Reply New Message

Back To Forum List View

imtesty

Rank: Vice President [?]

Points: 1210 [?]

Votes: 21 Score: 4.1 [?]

Your Vote:

Please Log In to Vote

Did you know? You can earn activity points by filling your profile with information about yourself (what city you live in, your favorite team, blogs etc.)

Dec 2016 article - apologies if already posted. Didn't see it in "Link Library"

posted on Sep 27, 2017 05:17AM

http://www.ejcancer.com/article/S0959-8049(16)32858-1/abstract

http://www.ejcancer.com/article/S0959-8049(16)32858-1/pdf

S. Attwell, K. Norek, R. Jahagirdar, C. Calosing, S. Lakhotia, E. Campeau, H. Hansen

The investigational drug ZEN-3694, a novel BET-bromodomain inhibitor, inhibits multiple tumor immune escape mechanisms and has the potential to combine with immunotherapies

European Journal of Cancer

December 2016 Volume 69, Supplement 1, Page S88

DOI: http://dx.doi.org/10.1016/S0959-8049(16)32858-1

2 Recommendations

Re: Dec 2016 article - apologies if already posted. Didn't see it in "Link Library"